• Vaccine Name: GSK1437173A
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Product Name: Herpes Zoster vaccine GSK1437173A
• Vaccine Ontology ID: VO_0004598
• Type: Subunit vaccine
• Status: Clinical trial
• Antigen: Glycoprotein E (gE) (Chlibek et al., 2013)
• US8 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Baboon Response

• Vaccination Protocol: This project was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline (Chlibek et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Immune Response: Cell-mediated and humoral immune responses immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE. gE/AS01B induced stronger immune responses than gE/AS01E (Chlibek et al., 2013).
• Side Effects: No vaccine-related severe adverse events were reported, and solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom (Chlibek et al., 2013).